Aspen Australia to support the registration and commercialisation of EMD-RX5

as an over-the-counter treatment in Australia.

"Aspen aims to be leaders in every product category we operate in. We are excited to continue this tradition by partnering with Emyria and supporting the registration and commercialisation of their unique product with large potential in the Australian market. We look forward to a long and successful partnership." - Aspen CEO, Trevor Ziman

Highlights of this announcement is here